New Delhi: Zydus Lifesciences on Saturday said it has received approval from the US health regulator to sell a generic drug for arthritis and other conditions in the US market. The company has received final approval from the US Food and Drug Administration (USFDA) for the market dexamethasone tablets (1 mg), the drug maker said in a statement.

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders.

According to IQVIA data, annual sales of dexamethasone tablets in the US were US$1.8 million.